Rivaroxaban (Xarelto)
Direct Oral Anticoagulant (NOAC) – Factor Xa Inhibitor
Rivaroxaban is a direct oral anticoagulant (DOAC/NOAC) that works by inhibiting Factor Xa, a key enzyme in the blood clotting cascade. At the 2.5 mg dose, it is used in combination with aspirin to reduce the risk of heart attack, stroke, and cardiovascular death in adults with acute coronary syndrome (ACS), coronary artery disease (CAD), or symptomatic peripheral arterial disease (PAD). This guide covers uses, dosage, side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts
Key Takeaways
- Rivaroxaban 2.5 mg is always taken together with aspirin (and sometimes clopidogrel) – never as monotherapy.
- Take one 2.5 mg tablet twice daily at approximately the same times each day, with or without food.
- The most important risk is bleeding – report any unusual or prolonged bleeding to your doctor immediately.
- Never stop taking rivaroxaban without consulting your doctor, as this increases the risk of heart attack and stroke.
- Tell your doctor about all medications you take, especially other blood thinners, NSAIDs, and certain antifungals or antibiotics.
What Is Rivaroxaban and What Is It Used For?
Rivaroxaban belongs to a class of medications known as direct oral anticoagulants (DOACs), also referred to as novel oral anticoagulants (NOACs). Unlike older anticoagulants such as warfarin, rivaroxaban works by directly and selectively inhibiting Factor Xa, a crucial enzyme in the coagulation cascade that is required for thrombin generation and ultimately clot formation. By blocking Factor Xa, rivaroxaban reduces the body's ability to form harmful blood clots without the need for regular blood monitoring.
At the low dose of 2.5 mg twice daily, rivaroxaban is specifically indicated for the prevention of atherothrombotic events in two main clinical scenarios. First, it is used in adults who have been diagnosed with acute coronary syndrome (ACS), a group of conditions that includes myocardial infarction (heart attack) and unstable angina (a severe form of chest pain caused by reduced blood flow to the heart). In these patients, rivaroxaban has been shown to significantly reduce the risk of recurrent cardiovascular events when added to standard antiplatelet therapy. The landmark ATLAS ACS 2-TIMI 51 trial demonstrated that rivaroxaban 2.5 mg twice daily, added to dual antiplatelet therapy with aspirin and clopidogrel, reduced the composite endpoint of cardiovascular death, myocardial infarction, and stroke by 16% compared to placebo.
Second, rivaroxaban 2.5 mg is indicated for adults diagnosed with coronary artery disease (CAD) or symptomatic peripheral arterial disease (PAD) who are at high risk of atherothrombotic events. The COMPASS trial showed that adding rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily reduced the rate of major adverse cardiovascular events by 24% compared to aspirin alone in patients with stable atherosclerotic vascular disease. The benefit was consistent across patients with CAD, PAD, or both.
When used after ACS, rivaroxaban is prescribed in combination with either aspirin alone, or aspirin plus clopidogrel (or ticlopidine). When used for stable CAD or PAD, it is typically combined with aspirin only. In some cases following a procedure to open a narrowed or blocked artery in the leg (such as peripheral revascularisation), the doctor may also prescribe clopidogrel for a short period in addition to aspirin. Rivaroxaban 2.5 mg should never be taken alone without an antiplatelet agent.
Rivaroxaban is available in several strengths (2.5 mg, 10 mg, 15 mg, and 20 mg), each indicated for different conditions. The 2.5 mg strength discussed in this article is specifically for cardiovascular protection in combination with aspirin. Higher doses are used for conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). Always ensure you are taking the correct strength as prescribed by your doctor.
What Should You Know Before Taking Rivaroxaban?
Contraindications
There are several situations in which you must not take rivaroxaban. Before starting treatment, your doctor will carefully assess whether any of these contraindications apply to you. You should inform your healthcare provider about your complete medical history, including all current and past medical conditions.
Do not take rivaroxaban if you:
- Are allergic to rivaroxaban or any of the other ingredients in the tablet (including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, and magnesium stearate).
- Are experiencing active significant bleeding, such as a gastrointestinal haemorrhage or intracranial bleeding.
- Have a disease or condition in any organ that increases the risk of serious bleeding, such as an active peptic ulcer, recent brain or spinal cord injury, recent brain or eye surgery, or known oesophageal varices.
- Are taking other anticoagulant medications (such as warfarin, dabigatran, apixaban, or heparin), except during the process of switching between anticoagulant treatments or when a venous or arterial catheter is being flushed with heparin to keep it open.
- Have had ACS and previously suffered a stroke or transient ischaemic attack (TIA).
- Have CAD or PAD and previously had a haemorrhagic stroke, a lacunar stroke, or an ischaemic non-lacunar stroke within the past month.
- Have liver disease leading to increased bleeding risk (including coagulopathy).
- Are pregnant or breastfeeding.
Warnings and Precautions
Talk to your doctor or pharmacist before taking rivaroxaban if any of the following conditions apply to you. Your doctor will need to determine whether rivaroxaban is appropriate for you and whether additional monitoring is required.
Increased bleeding risk: You should be particularly cautious if you have severe kidney disease (as impaired renal function affects drug levels), bleeding disorders, very high blood pressure not controlled by medication, gastrointestinal conditions that may lead to bleeding (such as inflammatory bowel disease, gastritis, oesophagitis, or gastrointestinal tumours), or blood vessel problems in the back of the eye (retinopathy).
Other risk factors: Additional caution is required if you have bronchiectasis or a history of pulmonary bleeding, if you are over 75 years of age, if you weigh less than 60 kg, if you have CAD with severe symptomatic heart failure, if you have a prosthetic heart valve, or if you have been diagnosed with antiphospholipid syndrome (an autoimmune condition that increases clotting risk).
Rivaroxaban must not be used in combination with certain other antiplatelet agents such as prasugrel or ticagrelor, except for aspirin and clopidogrel/ticlopidine.
If you need surgery or a procedure involving a catheter or injection into your spine (such as epidural or spinal anaesthesia), there is a risk of developing a spinal or epidural haematoma, which can cause permanent paralysis. It is critically important to take rivaroxaban at exactly the times your doctor specifies before and after such procedures. Seek immediate medical attention if you develop numbness, weakness in your legs, or bowel/bladder problems after spinal anaesthesia.
Pregnancy and Breastfeeding
Rivaroxaban is contraindicated during pregnancy and breastfeeding. Animal studies have shown reproductive toxicity, and rivaroxaban crosses the placental barrier. If you are of childbearing potential, you must use effective contraception while taking rivaroxaban. If you become pregnant while taking this medication, inform your doctor immediately so that an alternative treatment plan can be arranged.
It is not known whether rivaroxaban passes into human breast milk in clinically significant amounts. However, animal studies have demonstrated excretion in milk. Your doctor will advise against breastfeeding while taking rivaroxaban.
Driving and Operating Machinery
Rivaroxaban may cause dizziness (a common side effect) and fainting (an uncommon side effect). If you experience these symptoms, you should not drive, cycle, or operate machinery until the effects have resolved. You are responsible for assessing whether you are fit to perform these activities.
Excipient Information
Rivaroxaban tablets contain lactose (milk sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The tablets also contain less than 1 mmol (23 mg) sodium per tablet and are therefore considered essentially sodium-free.
How Does Rivaroxaban Interact with Other Drugs?
Drug interactions are a critical consideration when taking rivaroxaban. The medication is metabolised primarily through the cytochrome P450 3A4 (CYP3A4) enzyme pathway and is also a substrate of P-glycoprotein (P-gp). Drugs that affect these pathways can significantly alter rivaroxaban blood levels, either increasing the risk of bleeding or reducing the drug's effectiveness.
Always tell your doctor or pharmacist about all medications you are taking, have recently taken, or may take in the future, including over-the-counter medicines, herbal remedies, and supplements.
Drugs That Increase Rivaroxaban Levels (Higher Bleeding Risk)
The following medications can increase the concentration of rivaroxaban in your blood, thereby increasing the risk of bleeding. Your doctor may need to adjust your dose, choose an alternative treatment, or monitor you more closely.
| Drug / Drug Class | Mechanism | Clinical Significance |
|---|---|---|
| Ketoconazole (oral tablets) | Strong CYP3A4 and P-gp inhibitor | Significant increase in rivaroxaban levels; avoid combination |
| Ritonavir (and other HIV protease inhibitors) | Strong CYP3A4 and P-gp inhibitor | Significant increase in rivaroxaban levels; avoid combination |
| Itraconazole, Voriconazole, Posaconazole | Azole antifungal; CYP3A4 inhibitor | Increased bleeding risk; use with caution |
| Clarithromycin, Erythromycin | Macrolide antibiotic; moderate CYP3A4 inhibitor | Moderate increase in rivaroxaban levels; monitor closely |
| Fluconazole | Moderate CYP3A4 inhibitor | Moderate increase; use with caution |
| Dronedarone | CYP3A4 and P-gp inhibitor | Increased rivaroxaban exposure; limited clinical data |
Drugs That Increase Bleeding Risk
The following medications increase the risk of bleeding when taken with rivaroxaban, even without affecting rivaroxaban blood levels directly. This is because they independently impair haemostasis through different mechanisms.
- Other anticoagulants (warfarin, dabigatran, apixaban, enoxaparin, heparin) – concomitant use is generally contraindicated except during treatment switching.
- Antiplatelet agents (clopidogrel, prasugrel, ticagrelor) – prasugrel and ticagrelor must not be used with rivaroxaban 2.5 mg. Only aspirin and clopidogrel/ticlopidine are permitted.
- NSAIDs (naproxen, ibuprofen, diclofenac) – increase gastrointestinal bleeding risk; use with caution and consider gastroprotective therapy.
- SSRIs and SNRIs (fluoxetine, sertraline, venlafaxine, duloxetine) – impair platelet function and may increase bleeding risk.
Drugs That Decrease Rivaroxaban Effectiveness
The following medications can reduce rivaroxaban blood levels, potentially making it less effective at preventing blood clots. Your doctor should be informed if you are taking any of these.
- Rifampicin – a strong CYP3A4 and P-gp inducer that significantly reduces rivaroxaban levels. Avoid concomitant use.
- Phenytoin, Carbamazepine, Phenobarbital – antiepileptic drugs that induce CYP3A4 and may reduce rivaroxaban effectiveness.
- St. John’s Wort (Hypericum perforatum) – a herbal remedy that induces CYP3A4 and P-gp, potentially reducing anticoagulant effect.
If your doctor determines that you are at increased risk of developing gastric or duodenal ulcers (particularly when rivaroxaban is combined with aspirin and/or clopidogrel), they may prescribe preventive ulcer therapy such as a proton pump inhibitor (PPI).
What Is the Correct Dosage of Rivaroxaban?
Adults
The standard recommended dose of rivaroxaban for cardiovascular protection is 2.5 mg taken orally twice daily. You should take one tablet in the morning and one tablet in the evening, at approximately the same times each day. Consistency in timing helps maintain stable drug levels in your blood.
Rivaroxaban 2.5 mg can be taken with or without food. If you have difficulty swallowing the tablet whole, speak with your doctor about alternative administration methods. The tablet can be crushed and mixed with water or applesauce immediately before taking it. If necessary, your doctor can also administer the crushed tablet through a nasogastric feeding tube.
| Indication | Rivaroxaban Dose | Co-administered Therapy | Duration |
|---|---|---|---|
| Acute Coronary Syndrome (ACS) | 2.5 mg twice daily | Aspirin 75–100 mg/day ± clopidogrel 75 mg/day (or ticlopidine) | As determined by physician; started after ACS stabilisation |
| Coronary Artery Disease (CAD) | 2.5 mg twice daily | Aspirin 75–100 mg/day | Long-term as directed by physician |
| Peripheral Arterial Disease (PAD) | 2.5 mg twice daily | Aspirin 75–100 mg/day; ± clopidogrel short-term after revascularisation | Long-term as directed by physician |
When to Start Treatment
After acute coronary syndrome: Treatment with rivaroxaban should be started as soon as possible after the ACS has been stabilised, and at the earliest 24 hours after hospital admission. Treatment should begin at the time when parenteral (injectable) anticoagulation therapy would normally be discontinued. Your doctor will determine the exact timing.
For stable CAD or PAD: Your doctor will advise you on when to begin treatment based on your individual cardiovascular risk assessment and overall health status.
Children and Adolescents
Rivaroxaban 2.5 mg tablets are not recommended for individuals under 18 years of age. There is insufficient clinical data on the use of rivaroxaban at this dose in children and adolescents for cardiovascular indications.
Elderly Patients
No dose adjustment is specifically required for elderly patients. However, patients over 75 years of age may have an increased risk of bleeding and should be monitored more closely. The prescribing physician will weigh the benefits of anticoagulation against the bleeding risk on an individual basis, taking into account renal function, body weight, and concomitant medications.
Missed Dose
If you miss a dose of rivaroxaban 2.5 mg, do not take a double dose to make up for the forgotten one. Simply take the next dose at the usual time. Taking a double dose increases the risk of bleeding without providing additional therapeutic benefit.
Overdose
If you take too much rivaroxaban, or if a child accidentally ingests the medication, contact your doctor, go to the nearest emergency department, or call your local poison control centre immediately. An overdose of rivaroxaban increases the risk of bleeding. There is no widely available specific antidote for rivaroxaban, although andexanet alfa (Andexxa/Ondexxya) has been approved in some countries as a reversal agent for Factor Xa inhibitors in cases of life-threatening or uncontrolled bleeding.
Take rivaroxaban regularly for as long as your doctor prescribes it. Do not stop taking this medication without first consulting your doctor. Abruptly discontinuing rivaroxaban may increase your risk of having another heart attack, stroke, or other cardiovascular event. If you are concerned about side effects or wish to stop treatment, discuss this with your doctor first.
What Are the Side Effects of Rivaroxaban?
Like all medicines, rivaroxaban can cause side effects, although not everybody gets them. Because rivaroxaban is an anticoagulant (blood thinner), its most important side effect is bleeding. Excessive bleeding can potentially be life-threatening and may cause a sudden drop in blood pressure (shock). In some cases, bleeding may not be immediately apparent (internal bleeding).
Contact your doctor or go to the emergency department immediately if you experience: bleeding in the brain or skull (symptoms may include severe headache, one-sided weakness, vomiting, seizures, decreased consciousness, neck stiffness); prolonged or heavy bleeding; unusual weakness, tiredness, paleness, dizziness, breathlessness, or chest pain; severe skin rash spreading over the body, blisters, or mucous membrane sores; swelling of face, lips, tongue, or throat with difficulty breathing (anaphylaxis).
Common
May affect up to 1 in 10 people
- Anaemia (reduction in red blood cells), causing paleness, weakness, or breathlessness
- Gastrointestinal bleeding, urogenital bleeding (including blood in urine and heavy menstrual bleeding)
- Nosebleeds (epistaxis), gum bleeding
- Bleeding in the eye (including from conjunctiva)
- Bleeding into tissue or body cavities (haematoma, bruising)
- Coughing up blood (haemoptysis)
- Skin or subcutaneous bleeding
- Post-procedural bleeding, wound oozing
- Swelling in arms or legs, pain in extremities
- Impaired renal function (observed in lab tests)
- Fever, abdominal pain, nausea, vomiting, constipation, diarrhoea
- Low blood pressure (may cause dizziness or fainting on standing)
- Decreased general strength and energy (fatigue), headache, dizziness
- Skin rash, itching (pruritus)
- Elevated liver enzymes in blood tests
Uncommon
May affect up to 1 in 100 people
- Bleeding in the brain or inside the skull (intracranial haemorrhage)
- Bleeding into a joint (haemarthrosis), causing pain and swelling
- Thrombocytopenia (low platelet count)
- Allergic reactions, including allergic skin reactions
- Impaired liver function (observed in lab tests)
- Elevated bilirubin, pancreatic or liver enzymes, or platelet count
- Fainting (syncope), rapid heartbeat (tachycardia)
- Dry mouth, urticaria (hives)
- General feeling of being unwell (malaise)
- Angioedema and allergic oedema
Rare
May affect up to 1 in 1,000 people
- Bleeding into a muscle
- Cholestasis (reduced bile flow), hepatitis including hepatocellular damage
- Jaundice (yellowing of skin and eyes)
- Localised oedema (swelling)
- Pseudoaneurysm (groin haematoma after cardiac catheterisation)
Very Rare
May affect up to 1 in 10,000 people
- Eosinophilic pneumonia (accumulation of eosinophils causing lung inflammation)
- Stevens-Johnson syndrome / toxic epidermal necrolysis (severe skin reactions with spreading rash, blisters, and mucous membrane sores)
- DRESS syndrome (drug reaction with rash, fever, internal organ inflammation, and abnormal blood values)
- Anaphylactic reactions including anaphylactic shock
Frequency Not Known
Reported in post-marketing surveillance
- Renal failure following a severe bleeding episode
- Renal bleeding, sometimes with blood in urine, leading to impaired kidney function (anticoagulant-related nephropathy)
- Compartment syndrome after a bleed (increased pressure in muscles of arms or legs causing pain, swelling, altered sensation, numbness, or paralysis)
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority (such as the FDA in the United States, MHRA in the United Kingdom, or EMA in Europe) to help improve drug safety information.
How Should You Store Rivaroxaban?
Keep rivaroxaban out of the sight and reach of children at all times. Do not use this medication after the expiry date printed on the carton and each blister pack after “EXP.” The expiry date refers to the last day of the stated month.
Rivaroxaban tablets do not have any special storage requirements. Store at room temperature in the original packaging to protect from moisture. Do not discard medications via wastewater or household waste. Ask your pharmacist about proper disposal methods for medicines you no longer use. These measures help protect the environment.
What Does Rivaroxaban Contain?
Active Ingredient
Each tablet contains 2.5 mg rivaroxaban as the active substance. Rivaroxaban is a synthetic, small-molecule direct Factor Xa inhibitor with a molecular weight of 435.88 g/mol. It is highly selective for Factor Xa and does not require antithrombin III as a cofactor for its anticoagulant activity, which distinguishes it from heparin-based therapies.
Inactive Ingredients (Excipients)
Tablet core: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, magnesium stearate.
Film coating: Hypromellose, titanium dioxide (E 171), macrogol, yellow iron oxide (E 172).
Appearance and Pack Sizes
Rivaroxaban 2.5 mg film-coated tablets are yellow, round, biconvex, approximately 5 mm in diameter, debossed with “2.5” on one side and plain on the other. Available pack sizes vary by manufacturer and may include 20, 28, 56, 100, 168, and 196 tablets. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Rivaroxaban
Rivaroxaban 2.5 mg is used to reduce the risk of major cardiovascular events (heart attack, stroke, and cardiovascular death) in adults with acute coronary syndrome (ACS), coronary artery disease (CAD), or symptomatic peripheral arterial disease (PAD). It is always used in combination with aspirin and sometimes with clopidogrel. Higher doses of rivaroxaban (10–20 mg) are used for other conditions such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Yes, rivaroxaban 2.5 mg can be taken with or without food. If you have trouble swallowing tablets, the tablet may be crushed and mixed with water or applesauce immediately before taking it. Your doctor may also give the crushed tablet through a nasogastric tube if needed.
If you forget to take a dose of rivaroxaban 2.5 mg, do not take a double dose. Simply take the next dose at the regular scheduled time. Taking extra doses increases the risk of bleeding without improving protection.
The most common side effects of rivaroxaban include various forms of bleeding (nosebleeds, gum bleeding, gastrointestinal bleeding, blood in urine), anaemia, bruising, dizziness, headache, nausea, abdominal pain, and elevated liver enzyme levels in blood tests. Bleeding is the most clinically important side effect. Seek immediate medical attention for any signs of severe or unusual bleeding.
No. You should never stop taking rivaroxaban without consulting your doctor first. Stopping the medication abruptly can increase your risk of another heart attack, stroke, or cardiovascular death. Your doctor will advise you on treatment duration and on how to safely discontinue the medication if necessary.
Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits Factor Xa, while warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X). Key differences: rivaroxaban has a predictable dose-response relationship and does not require routine INR blood monitoring; it has fewer dietary interactions (warfarin is significantly affected by vitamin K-containing foods); it has a rapid onset (2–4 hours vs. days for warfarin); and it uses fixed dosing. Warfarin, however, has a well-established reversal agent (vitamin K) and decades of clinical experience. Andexanet alfa is now available as a specific reversal agent for rivaroxaban in some countries.
References
All medical information on this page is based on peer-reviewed evidence, international clinical guidelines, and regulatory documents. Evidence level: 1A (systematic reviews and randomised controlled trials).
- Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19. doi:10.1056/NEJMoa1112277 (ATLAS ACS 2-TIMI 51 trial)
- Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. doi:10.1056/NEJMoa1709118 (COMPASS trial)
- Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi:10.1016/S0140-6736(17)32409-1
- European Medicines Agency (EMA). Xarelto (rivaroxaban) Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu
- U.S. Food and Drug Administration (FDA). Xarelto (rivaroxaban) Prescribing Information. Available at: fda.gov
- British National Formulary (BNF). Rivaroxaban. Available at: bnf.nice.org.uk
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425
- Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi:10.1093/eurheartj/ehaa575
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd list, 2023.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with Factor Xa inhibitors. N Engl J Med. 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians specialising in clinical pharmacology, cardiology, and haematology. Our editorial process follows the GRADE evidence framework, and all content is independently reviewed without pharmaceutical industry sponsorship.
iMedic Medical Editorial Team – specialists in clinical pharmacology and cardiovascular medicine with documented academic background and clinical experience.
iMedic Medical Review Board – independent panel reviewing all content against EMA SmPC, FDA labelling, BNF, and international clinical guidelines (ESC, AHA/ACC).
All claims in this article are supported by Level 1A evidence: systematic reviews and meta-analyses of randomised controlled trials. Key references include the ATLAS ACS 2-TIMI 51 and COMPASS landmark trials, EMA and FDA regulatory documents, and ESC clinical practice guidelines. This article has no commercial funding and no pharmaceutical company sponsorship.